1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with zelandopam in 1 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (zelandopam) | Trials (zelandopam) | Recent Studies (post-2010) (zelandopam) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 17 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, Y; Asano, M; Honda, K; Inagaki, O; Kasai-Nakagawa, C; Takanashi, M; Takenaka, T; Takizawa, K; Tanaka, A; Uchida, W; Yatsu, T | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and zelandopam
| Article | Year |
|---|---|
Renal effect of YM435, a new dopamine D1 receptor agonist, in anesthetized dogs.
Topics: Anesthesia; Angiotensin II; Animals; Benzazepines; Dogs; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Electric Stimulation; Female; Hemodynamics; Infusions, Intravenous; Isoquinolines; Kidney; Kidney Diseases; Kidney Function Tests; Male; Platelet Activating Factor; Receptors, Dopamine D1; Renal Circulation; Tetrahydroisoquinolines; Vasodilator Agents | 1997 |